Cervical cancer in women diagnosed at the National Health Laboratory, Sudan: A call for screening by Husain, N et al.
 
© Sudan JMS Vol. 6, No.3. Sept 2011      183 
 
bÜ|z|ÇtÄ TÜà|vÄx 
Cervical cancer in women diagnosed at the National Health Laboratory, Sudan: 
A call for screening 
N Husain 1, T Helali 2, M Domi 3, S Bedri 4 
Abstract 
Background: Cancer of the cervix is the second most prevalent cancer of women to date in the 
Sudan, in a concerted review of the records of the hospital-based cancer registry of the Radiation & 
Isotope Centre of Khartoum (RICK). However, in spite of a wealth of data, this is the first study to 
date describing the histopathologic prevalence of cervical cancer in the Sudan. 
Objectives:  To identify the percentage and clinicopathological pattern of cervical cancer cases 
diagnosed at Histopathology Department, National Health Laboratory (NHL) in Khartoum, Sudan.  
Material and Methods: This is a cross-sectional, descriptive study conducted at the NHL.  All 
cases with histopathological diagnosis of cervical neoplasm in the period from 2004-2009 were 
reviewed.  Patients’ clinical data were obtained from clinical records. Exclusion criteria included 
inadequate clinical information and unavailability of both Hematoxylin and Eosin stained (H&E) 
sections and formalin-fixed paraffin-embedded (FFPE) blocks. The WHO classification of cancer 
of the cervix (2003) was used to describe disease type. 
SPSS data analysis was applied. 
Results: A total of 287 cases were reviewed and 195 cases were included in the study.  The mean 
of cervical cancer cases diagnosed per year at NHL is 7.9%. The commonest age group affected 
was patients grouped between 41- 60 years (52%) followed by 61-80 years (26.3%). Histologically, 
95.9% of the cases were carcinomas. Squamous cell carcinomas were 90.9%, Adenocarcinomas 
4.8%, and other epithelial tumours were 4.3%. Of the Squamous carcinomas, 98.8% were invasive 
and 1.2% intraepithelial (cervical intraepithelial neoplasia). 
The majority of case presentations were that of a protruding cervical mass. We noticed the 
commonest symptom being bleeding per vagina. 
Conclusion: To determine the incidence of cervical cancer in the Sudan a national population-
based registry is necessary. The mean age of patients presenting with cervical cancer to NHL is 
53.25 years. This is in keeping with the natural history of the human papilloma virus (HPV). The 
late presentation of patients with aggressive disease necessitates health education and cervical 
cancer screening as well as strict guidelines for medical record keeping in line with good medical 
practices, enabling good data collection for the newly established  population-based cancer registry. 
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ANCER of the cervix uteri is the 
second most common cancer among 
women worldwide, with an estimated 
529,409 new cases and 274,883 deaths in 
20081.  
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About 86% of the cases occur in developing 
countries, representing 13% of female 
cancers1.High-risk regions are East and West 
Africa with age-standardized incidence rate 
(ASR) greater than 30 per 100,000. These are 
followed by Southern Africa (26.8 per 
100,000), South-Central Asia (24.6 per 
100,000), South America and Middle Africa 
(ASRs 23.9 and 23.0 per 100,000)1. Rates are 
lowest in Western Asia, Northern America 
and Australia/New Zealand (ASRs less than 6 
per 100, 000) 1. Some Eastern and Central 
European countries have relatively high 
incidence such as Serbia2 where the ASR of 
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cervical cancer is 27.2 per 100,000 - twice as 
high as in Western European countries3.   The 
decline in rates of cervical cancer in Europe 
and North America is mainly due to the 
rigorous preventive measures adopted in these 
societies of cervical cancer screening via the 
Pap smear. 
According to hospital-based statistical data 
from the Radiation and Isotopes Centre of 
Khartoum (RICK), cervical cancer is the 
second most common cancer type among 
women in Sudan4.  
To date there is no national registry or 
epidemiological study published about this 
heath problem.  
It is almost two decades since Haral zur 
Hausen discovered the DNA of Human 
Papilloma Virus (HPV) type 16 and 18 in 
cervical cancers and implicated them as 
causative agents. Since then HPV has been 
well characterized as a causative agent for 
cervical cancer5. Of the more  than 100 
subtypes of the HPV have been identified 
with forty implicated or associated with 
genital infection but persistent genital 
infection with oncogenic HPV causes 
virtually all cases of cervical cancer6, 7.  HPV 
genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59 and 66 are considered to be high 
risk (HR HPV) and closely related to cervical 
oncogenesis 8-10. 
  Copies of HPV viral DNA are detected from 
90% of cervical cancer cells. Their E6 and E7 
gene products are known to inactivate the 
major tumor suppressors, p53 and 
retinoblastoma protein (Prb) and drive cells 
into an immortal phase with E6 gene products 
affecting the activity of telomerase5.  
The commonest cancer causing subtypes in 
Africa appear to be similar to other countries 
in both the developed and developing  
world11-14. 
Other factors such as smoking, 
immunosuppression, chlamydia infection, 
diet, oral contraceptives, multiple full-term 
pregnancies, young age at the first full-term 
pregnancy, poverty, diethylstilbestrol and 
family history of cervical cancer, may 
predispose to cervical cancer15. But the causal 
role of HPV in all cancers of the uterine 
cervix has been firmly established 
biologically and epidemiologically16. Other 
associations such as co-infection with HIV 
have also been established in some sub-
Saharan African countries17.   
The aim of this study is to identify the 
percentage and the clinicopathological pattern 
of cervical carcinomas found in the records of 
the Histopathology Department, National 
Health Laboratory (NHL) in Khartoum, 
Sudan, which receives the majority of 
specimens from different regions of the 
country.   
Material and Methods:  
This is a cross-sectional, descriptive study 
conducted at the Histopathology Department, 
NHL in Khartoum, Sudan.  All cases 
diagnosed histopatholgically as cervical 
tumour in the period 2004-2009 were studied 
and reclassified according to the WHO (2003) 
classification system by two 
histopathologists. An experienced third 
histopathologist was consulted in some cases. 
Squamous cell carcinomas were reclassified 
using the recommended two-tiered 
classification (keratinized and non-
keratinized) and assessed histologically for 
the degree of differentiation.                  
The patient's information was collected from 
the clinician’s request forms. Exclusion 
criteria included inadequate information and 
unavailability of both the Hematoxylin and 
Eosin (H&E) sections and the formalin-fixed 
paraffin-embedded (FFPE) blocks. The data 
were analyzed using the Statistical Package of 
Social Sciences (SPSS). P value less than 
0.05 was considered statistically significant.  
Results:  
 In a review of the NHL histopathology 
department  a total of 287 cervical cancer 
cases diagnosed during the period 2004-2009 
in the NHL, 195 cases were included in the 
study. Exclusionary criteria for the 92 cases 
included insufficient clinical data or 
demographic information or unavailability of 
FFPE blocks. In the year 2004, 65 invasive 
cervical cancer (ICC) cases were diagnosed. 
It represents 12.87% of all cancer cases 
diagnosed in the same year. In the 2005, 
11.82% of cancer cases were ICC, while it 
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was 8.10% in 2008. In average, cervical 
cancer accounts approximately for 7.9% of 
cancer cases diagnosed annually in the NHL. 
The commonest age group at presentation was 




Figure1:Distribution of cases according to 
age.  
 
Mean age at presentation was 53.3(± 3.5 SD).  
Vaginal bleeding was the presenting symptom 
in 88.7% of the studied cases and presence of 
a cervical mass protruding through vagina 
accounted for 54.3% of the studied cases in 
which vaginal examination findings were 
registered (Figure 2).    
 
 
Figure 2: Distribution of epithelial tumors 
among the studied cases ( No=187). 
 
Histologically, 95.9% of the cases reviewed 
were carcinomas. Of the carcinomas 90.9% 
were squamous, 4.8% were adenocarcinomas, 
and 4.3% were other epithelial tumours 
(Figure 3). The squamous cell carcinomas 




Figure 3: Distribution of squamous neoplasms 




Figure 4: Findings of vaginal examination 
among the studied cases. 
 
Non-keratinizing squamous cell carcinomas 
(SCC) accounted for 66.1% and the 
keratinizing SCC for 24.4% of SCC types. 
Grading revealed 22.8% well differentiated, 
44.9% moderately differentiated and 22.8 
were poorly differentiated SCC.  
Discussion: 
The declining incidence of ICC in the NHL in 
this study did not reflect the real situation, as 
many patients who were diagnosed in private 
or newly established histopathology 
laboratories were not included in the study. 
More systematic and national population-
based registries and accurate medical record 
keeping are needed to better determine the 
incidence of cervical cancer in Sudan. 
In a meta-analysis, de Sanjose S et al found 
that worldwide HPV prevalence in women  
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with normal cytology at any given point of 
time is approximately 10.0% indicating that it 
is one of the most common sexually 
transmitted infections. About 70.1% of 
invasive cervical cancers in the world are 
attributed to HPVs 16 or 18. HPV-16 is 
consistently the most common type and HPV-
18 the second with some minor regional 
differences18, 19.   
Detrimental to HPV infection and 
transmission are sexual behavior patterns 
across populations and age groups rather than 
individual sexual practices, particularly 
sexual behavior considered high risk, such 
non-monogamous relationships, early or 
premature sexual practice as a teenager20. 
Another pertinent issue studying population 
patterns and their sexual behavior is that of 
migrant population with high risk behavior 
puts those of host country at high risk of 
developing cervical cancer, particularly so 
because they too are at high risk of 
developing ICC related to HPV infection20.  
Sudan has a large migrant population from 
neighboring African countries. The current 
study showed that women diagnosed at the 
NHL as having cervical cancer are at a higher 
age (Figure 1).  This is in keeping with the 
natural history of HPV infection. The mean 
age at presentation is 53.3 which is higher 
compared to some studies 21-24 while similar 
to others where HPV infection is still 
prevalent25-27.     A similar study published 
recently from Iran described a similar average 
age group incidence of 53.6 years as ours and 
higher percentage of adenocarcinomas (20%) 
when compared to this study. However other 
similarities include a very low rate (< 2%) of 
cytology screening in Iran28.   
The most common histopathological type in 
this study was squamous cell carcinoma and 
the majority of cases (66.1%) were large cell 
non-keratinizing. The histopathological 
features of cervical carcinomas in Sudan 
appear to be similar to those found in United 
States, Europe, Asia, and Africa24, 29-32. 
Nearly all studied cases were invasive 
cervical cancers (98.8%) and where vaginal 
examinations findings were registered, 54.3% 
of the patients presented with a protruding 
cervical mass, i.e. stage II or more.  This late 
presentation is found only in developing 
countries21. Late tumour stage correlates with 
unscreened populations, however if at risk 
populations are screened regularly, mortality 
is reduced by (70%) 33, 34. Screening for 
cervical cancer, particularly the Pap smear, 
has saved multitudes of lives in developed 
countries. However, this is not the case in 
developing countries where the majority of 
women remain unscreened and at high risk of 
developing invasive cervical cancer, due to 
the limited resources of their health 
infrastructure. Incidence too, remains very 
high for cervical cancer at 86%35, 36.  
The Pap smear for short is the Papanicolaou 
test, a cytopathology screening test, 
developed by Georgios Papanikolaou in the 
1950s of the last century, and has been 
instrumental in decreasing the incidence of 
cervical cancer in the Americas and Europe.  
Organized and systematic programs of 
cervical cytology that have been established 
worldwide in both developed countries have 
lowered the rates of cervical cancer and 
increased the detection of preinvsive and 
dysplastic lesions, which can be easily cured. 
However, cervical cytology programs require 
well organized, quality assured, infrastructure 
and trained health professionals and  
financing 37, 38. 
Hurdles, exist to date to establishing cervical 
cytology screening programs in developing 
countries as has been identified in countries 
of Latin America, where cervical cancer 
incidence is fluctuating. Many impediments 
to proper screening have been identified, 
including, poverty, poor health infrastructure, 
and lack of awareness of the at risk 
population39-41. 
Therefore, a number of different tests have 
been developed and investigated over the 
years as alternative screening tests to 
cytology, particularly for low income settings, 
where programs cannot be implemented 
properly.  They include:  HPV-DNA testing, 
Visual inspection methods, Colposcopy, Polar 
Probe and optical detection methods41. Visual 
inspection (with acetic acid or Lugol’s iodine) 
and HPV-DNA testing which is being 
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considered as an additional test to the 
conventional Pap screening test and as a 
primary screening test in older women are the 
two most widely studied alternative 
approaches to cervical cancer prevention. 
Cervical precursors that are most likely to 
progress to cervical cancer are better 
identified by molecular tests, particularly tests 
that could detect integrated HPV-DNA or its 
products41. Maintaining routine quality 
controls of the screening procedures and 
organizing the proper follow-up of women 
with abnormal screening results are essentials 
of the success of the screening program 42.    
 In the 2009 New England Journal of 
Medicine publication, Sankaranarayanan et al, 
described a cluster-randomized trial of Indian 
women from 52 villages, more than 130 000 
women participated. In the study they 
compare HPV genotype testing (a one time 
event), cytology based screening and thirdly 
visual inspection of the cervix with acetic 
acid. The conclusion of this study suggests 
that perhaps a one time HPV test of a sexually 
active female, between the ages of 30-60 
years may be more accurate and more 
affordable of limited resource settings13. 
In Sudan, cervical cancer screening programs 
has not been implemented by the Federal 
Ministry of Health although it has been 
prioritized in its WHO supported National 
Cancer Control Program and the majority of 
women have never been screened.  The 
authors think that lack of screening, women's 
lack of knowledge about reproductive health 
issues, centralization of health care services, 
and personal barriers that women experience 
in accessing health care may attribute to the 
late presentation of cervical cancer cases in 
Sudan. In spite of other experiences in other 
African and developing countries, there still 
exist barriers to proper cervical cancer 
screening and this even in our societies were 
awareness of the severity and knowledge that 
cervical caner can be cured11,12,43. This 
highlights the need for screening of cervical 
cancer for early detection and management in 
addition to educational and organizational 
preventive strategies, as well as further 
studies understanding factors leading to lack 
of access to knowledge and basic infra 
structure needed to establish programs, 
particularly in rural settings. 
Therefore, a serious and concerted effort is 
needed to reduce the prevalence of cervical 
cancer in Sudan. The authors of this paper 
would like to acknowledge the role of the 
Regional and Federal Ministries of Health in 
the Sudan and local NGOs in their efforts to 
combat and decrease the incidence of cervical 
cancer, particularly with the initiation of a 
population based caner registry in 2010. 
However, policy makers need to get on board 
to prevent this otherwise fatal disease by 
endorsing a feasible screening program for 
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